Canopy Growth (NYSE:CGC) and Foamix Pharmaceuticals (NASDAQ:FOMX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
This is a summary of recent ratings for Canopy Growth and Foamix Pharmaceuticals, as reported by MarketBeat.com.
Canopy Growth currently has a consensus target price of $64.82, suggesting a potential upside of 43.08%. Foamix Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 553.85%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Foamix Pharmaceuticals is more favorable than Canopy Growth.
Volatility and Risk
Canopy Growth has a beta of 4.17, meaning that its stock price is 317% more volatile